Canaccord analyst Sumant Kulkarni downgraded Zynerba Pharmaceuticals to Hold from Buy with a price target of $1.11, down from $10, after the company entered into an agreement to be acquired by Harmony Biosciences (HRMY). The stock is no longer trading on fundamentals, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ZYNE: